• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. (greenmedinfo.com)
  • We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. (greenmedinfo.com)
  • PLATO was a head-to-head outcomes study of ticagrelor plus aspirin versus the active comparator, clopidogrel plus aspirin, and was designed to establish whether ticagrelor could achieve meaningful cardiovascular endpoints in ACS patients. (eurekalert.org)
  • Watch this expert-led 90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and the resultant practical applications for patient care. (pri-med.com)
  • Eisai Announces Long-Term Cardiovascular Outcomes Data fo. (pharmiweb.com)
  • Eisai Inc. announced today that results from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily were presented at the European Society of Cardiology (ESC) Congress 2018 and concurrently published in the New England Journal of Medicine. (pharmiweb.com)
  • Medline, Embase, and the Cochrane Library were searched up to February 2018 for studies reporting on cardiovascular outcomes with macrolides. (asm.org)
  • Outcomes were pooled using random-effects models and odds ratios (OR), and 95% confidence intervals (CI) were calculated for arrhythmia, cardiovascular death, and myocardial infarction (MI). (asm.org)
  • This meta-analysis was dominated by three large multicenter randomized trials: the "Normal Hematocrit Study" [ 4 ] (NHS, n = 1233), which enrolled patients receiving hemodialysis, the "Correction of Hemoglobin and Outcomes In Renal insufficiency" study (5) (CHOIR, n = 1432) and the "Cardiovascular Risk reduction by Early Anaemia Treatment with Epoietin beta" study [ 6 ] (CREATE, n = 603) both conducted in patients with CKD not receiving dialysis. (biomedcentral.com)
  • SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (springer.com)
  • While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30-40% reductions in heart failure hospitalisation (HFH) and cardiovascular and all-cause deaths in patients treated with empagliflozin were highly impressive and unexpected. (springer.com)
  • In this review, we discuss briefly why cardiovascular endpoint trials for new diabetes agents are required and describe the results of the first four such trials to have reported, as a precursor to understanding why the EMPA-REG Outcomes results came as a surprise. (springer.com)
  • Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. (nih.gov)
  • Comprehensive CV risk reduction in DM should focus on aggressive management of glycemic status, blood pressure, and lipids, the use of antithrombotic agents, as well as therapeutic lifestyle modification including regular physical activities and prudent diet. (medscape.com)
  • Accordingly, inhibition of this enzyme is emerging as a major therapeutic strategy for the treatment of hyperglycemia-induced cardiovascular pathologies. (nih.gov)
  • Particular emphasis is given to insights derived from therapeutic interventions with lifestyle modification, cardiovascular drugs, antidiabetic drugs, and other related treatments. (ahajournals.org)
  • Some commonly used pesticides (for example, the organophosphate (OP) Malathion and the carbamate Sevin) and some common therapeutic drugs (the carbamates pyridostigmine [Mestinon] and physostigmine [Antilirium]) also inhibit acetylcholinesterase and can be considered 'nerve agents. (fas.org)
  • In other aspects of the invention, therapeutic agents may be delivered and/or a seal may be formed about the prosthesis to prevent a Type I failure. (google.com)
  • Methods of preparing devices for delivering at least one therapeutic agent to a target vessel in a mammal, the devices prepared by such methods, and uses of such devices for delivering a therapeutic agent, such as an antiproliferative agent, to a target vessel. (google.ca)
  • 1 . A method of delivering at least one therapeutic agent to a target vessel in a mammal, comprising contacting an outer surface of the target vessel with a device comprising a polymer and said at least one antiproliferative agent. (google.ca)
  • 8 . The method of claim 2 wherein said sheet is formed by casting a mixture of said polymer and said therapeutic agent. (google.ca)
  • 11 . The method of claim 1 wherein the device is a molten mass comprising said polymer and said at least one therapeutic agent. (google.ca)
  • A flexible and kink-proof intra-cavity delivery catheter for precise placement and injection of therapeutic agent(s) into and/or through the wall of a body cavity at a precise treatment site with even distribution throughout. (google.ca)
  • Precise amounts of the therapeutic agent are then quickly delivered through the needle assembly directly into the diseased body tissue. (google.ca)
  • The problems of overtreatment and undertreatment of the treatment site and the body with therapeutic agents, uneven distribution of therapeutic agents within the diseased treatment site, additional trauma to the treatment site, and long term blockage of body fluid distal to the treatment site via known drug delivery catheters are thereby eliminated. (google.ca)
  • said inner inflation balloon having a known and calibrated inflation rate and said tissue insertion needles having a known and calibrated length such that inflation of said internal inflation balloon causes said tips of said tissue insertion needles to extend through said portals and pierce the body tissue at a desired treatment site to a known and calibrated depth for the delivery of desired therapeutic agents. (google.ca)
  • We hypothesized that a pulmonary exposure to AgNP induces cardiovascular toxicity influenced by inflammation and vascular dysfunction resulting in expansion of cardiac I/R Injury that is sensitive to particle size and the capping agent. (ecu.edu)
  • Most of the nerve agents were originally synthesized in a search for insecticides, but because of their toxicity, they were evaluated for military use. (cdc.gov)
  • Since the introduction of organophosphorus (OP) compounds as nerve agents and pesticides, methods of dealing with their toxicity to humans have been intensely researched. (rsc.org)
  • AIMS: The aim of this study was to assess long-term safety of intravenous cardiovascular agents-vasodilators, inotropes and/or vasopressors-in acute heart failure (AHF). (uzh.ch)
  • This heightened awareness of potentially harmful CV effects of otherwise effective hypoglycemic drugs resulted in regulatory mandates for CV outcome trials to ascertain the safety of newer anti-hypoglycemic agents appearing on the market. (medscape.com)
  • Cardiovascular drugs control and treat various heart conditions. (sharecare.com)
  • Since G protein coupled receptors (GPCRs) are target of forty percent of clinically used drugs, here we discuss the newly identified cardioprotective agents that bind GPCRs of adrenalin, adenosine, melatonin, ghrelin, galanin, apelin, prokineticin and cannabidiol. (frontiersin.org)
  • However, most of the anticancer drugs display a wide array of cardiovascular toxicities, leading to interruption of cancer therapies and maladaptive remodeling in hearts, affecting the short- and long-term quality of life ( 2 - 4 ). (frontiersin.org)
  • We also discuss whether other drugs in this class are likely to show similar cardiovascular benefits. (springer.com)
  • Side effect rates for the anticholinergic drugs were compared using univariate (Chi-square) and multivariate (logistic regression) methods.Results The files from the FDA held data for 36 491 different subjects, of whom 2610 (7.15%) experienced a cardiovascular or neurovascular side effect. (edu.au)
  • Further studies on the association between anticholinergic drugs and cardiovascular and neurovascular side effects are recommended. (edu.au)
  • The data on cardiovascular benefits are increasing, but as with all powerful drugs, they can't be used in all patients. (londoncardiovascularclinic.co.uk)
  • Inotropic agent s are drugs that influence the force of contraction of cardiac muscle and thereby affect cardiac output. (britannica.com)
  • Objectives The purpose of this study was to assess the frequency, manifestation, and severity of acute adverse reactions associated with administration of several gadolinium-based contrast agents to patients who underwent cardiac magnetic resonance (CMR) imaging in the EuroCMR (European Cardiovascular Magnetic Resonance) Registry multinational and multicenter setting. (onlinejacc.org)
  • Studies reporting an increased risk for cardiac toxicities with macrolide antibiotics have raised concern regarding their cardiovascular safety. (asm.org)
  • We sought to assess the cardiac safety of macrolide antibiotics as a class and of the individual agents by conducting a systematic review and network meta-analysis. (asm.org)
  • Exposure to both 20 and 110 nm AgNP resulted in exacerbation cardiac I/R injury 1 day following IT instillation independent of capping agent with 20 nm AgNP inducing marginally greater injury. (ecu.edu)
  • Conclusions: Exposure to AgNP may result in vascular dysfunction, a potentially maladaptive sensitization of the immune system to respond to a secondary insult (e.g., cardiac I/R) which may drive expansion of I/R injury at 1 and 7 days following IT instillation where the extent of injury could be correlated with capping agents and AgNP size. (ecu.edu)
  • Procoralan is the first pure heart rate-lowering agent and acts by selective inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarization in the sinus node and regulates heart rate. (medicalnewstoday.com)
  • It will be of interest to busy specialist physicians in cardiovascular medicine, cardiac and vascular surgery, and critical care, as well as primary care physicians and hospitalists who care for patients with these syndromes. (wiley.com)
  • Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. (wikipedia.org)
  • Class I agents are grouped by what effect they have on the Na+ channel, and what effect they have on cardiac action potentials. (wikipedia.org)
  • Ultrasound contrast agents (UCAs) have been in the echocardiographic "toolbox" for many years. (onlinejacc.org)
  • We describe our clinical experience with patients who had cardiovascular adverse drug reactions (CVADRs) with combination therapy. (biomedsearch.com)
  • Preliminary trials of long-term therapy with oral verapamil for control of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia suggest that this agent is effective for therapy of these arrhythmias. (annals.org)
  • The attachment of the agent to the enzyme is permanent (unless removed by therapy). (fas.org)
  • However, while the OP pesticides cause the same biological effects as nerve agents, there are some important differences in the duration of biological activity and response to therapy. (fas.org)
  • A new study has found that women who gave birth following fertility treatment had no long-term increased risk of death or major cardiovascular events compared to women who gave birth without fertility therapy. (medindia.net)
  • The author reviews clinical trial data on the effect of glucose control on CVD risk, the selection and timing of antihyperglycemic agents, the management of associated CVD risk factors, and strategies to improve patient adherence and acceptance-with the goal of assisting physicians in selecting appropriate management strategies for their patients with T2DM. (jaoa.org)
  • Therefore, the present study investigated the involvement of angiotensin II (Ang II) acting on the type 1 Ang II receptor (AT 1 ) in the cardiovascular dysfunctions evoked by both homotypic and heterotypic chronic emotional stresses in rats. (frontiersin.org)
  • Furthermore, initial concerns (now largely refuted [ 4 ]) about the cardiovascular safety of rosiglitazone led the US Food and Drug Administration to mandate that all new glucose-lowering agents must be tested for cardiovascular safety in post-marketing endpoint trials. (springer.com)
  • These agents inhibit platelet aggregation. (medscape.com)
  • Nerve agents inhibit acetylcholinesterase in tissue, and their effects are caused by the resulting excess acetylcholine. (fas.org)
  • Prescribed for cancer precisely because they inhibit fast growing or fast acting cells, chemotherapeutic agents cause neuropathy and chronic pain in approximately one third of the patients to whom they are administered. (neuropathydr.com)
  • This electrical interruption is misapplied when the agent is in contact with the myelin sheath of a health, active nerve cell and causes the nerve cell to "short out" and inhibit the necessary different potentials in the nodes of the myelin sheath. (neuropathydr.com)
  • Gadolinium-based contrast agents are considered generally safe in radiology practice. (onlinejacc.org)
  • The incidence of adverse reactions is relatively low compared with that of iodinated contrast agents used for computed tomography ( 2-7 ). (onlinejacc.org)
  • 2 Currently, there are many commercially produced US contrast agents (see Table 1 ) with common salient features. (uscjournal.com)
  • Participants in this program will also receive expert advice on using ADA and AACE/ACE guidelines appropriately as well as other strategic insights to improve care for their patients with T2DM and cardiovascular risk. (pri-med.com)